PVLA
The table below shows Palvella Therapeutics, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $206.39M | $63.57M | $70.43M | $75.63M | $19.36M | $19.73M |
| Short-term investments | $55.46M | - | - | - | $0.00 | $0.00 |
| Receivables | - | $0.00 | $0.00 | $0.00 | $373.00K | $1.49M |
| Inventory | - | - | - | - | - | - |
| Total current assets |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $263.23M |
| $66.94M |
| $73.75M |
| $79.44M |
| - |
| - |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | - | - | - | - | - | - |
| Total assets | $263.76M | $66.94M | $73.75M | $79.44M | $20.52M | $25.05M |
| Accounts payable | $5.44M | $3.48M | $4.56M | $4.44M | $801.00K | $969.00K |
| Total current liabilities | $9.12M | $10.31M | $9.62M | $8.98M | $4.25M | $6.35M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $31.45M | $28.25M | $25.97M | $23.86M | - | - |
| Retained earnings | -$151.22M | -$122.74M | -$111.39M | -$101.92M | -$326.33M | -$323.45M |
| Total equity | $232.31M | $38.68M | $47.78M | $55.58M | $16.27M | $18.70M |